Navigation Links
China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
Date:1/30/2008

SHANGHAI, China, Jan. 30 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) (''China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has launched a new bilingual corporate Web site under the domain name of http://www.chn-biotics.com .

The new Web site was created to strengthen communication and branding efforts with investors, customers and business partners. The site provides key information on China-Biotics, including corporate, industry and product information, corporate news, and important investor information such as access to SEC filings, investor presentations and earnings conference call webcasts. The Web site was designed in both English and Chinese by CCG Elite Investor Relations, China-Biotics' investor relations agency.

''We are excited to launch our new Web site as we strive to improve communication with customers and investors,'' said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "This valuable tool will enable us to educate consumers and investors about the growing importance of probiotics in both the Chinese and global markets. The site will also help us to deliver on our commitment to transparency as a U.S. publicly traded company.''

About China-Biotics, Inc.

Headquartered in Shanghai, China-Biotics, Inc. ("China-Biotics", "the Company'') was founded in 1999 and is one of China's largest suppliers of probiotics. Probiotics are beneficial live bacteria used as dietary supplements and food additives to improve intestinal health and digestion. The Company's product portfolio contains live microbials made with proprietary technology. Currently, these products are sold over-the-counter under the ''Shining'' brand through large distributors to more than 1,000 pharmacies and 100 supermarkets in Shanghai, Jiangsu and Zhejiang. Shining is one of the most recognized brands in Shanghai. China-Biotics plans to expand its retail sales to other major cities in China and will launch 300 Shining brand logistic centers in these cities during the next two years. The Company's flagship product, ''Shining Essence'', has been a profit driver since its launch in April 2001. There is a significant demand for probiotics for use in the bulk additive market, which is currently met by imports. China-Biotics is building a new plant which will increase its production capacity manifolds to capture this market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

CCG Elite Investor Relations

Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
2. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
3. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series
6. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
7. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
8. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
9. PennWell Launches Bio-Optics World Magazine and Web Site
10. DRI Capital Launches Structured Finance Fund
11. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 QIAGEN N.V. (NASDAQ: ... today announced the U.S. launch of its ipsogen ® JAK2 ... U.S. Food and Drug Administration as a qualitative in vitro diagnostic test for ... whole blood.* ... assay is processed on QIAGEN,s Rotor-Gene ® Q MDx system, which is ...
(Date:3/29/2017)... March 29, 2017 /PRNewswire/ - Last year,s petition to the ... the only efforts active to generate awareness on the importance of ... drugs in the healthcare market place. ... Earlier this month Health Advance ... of pharmaceutical and nutritional products, announced its endeavors on this ...
(Date:3/29/2017)... PETACH TIKVAH, Israel , ... Inc. (NASDAQ: BCLI), a leading developer of ... announced financial results for the year ended ... a highly successful and pivotal year for Brainstorm, with ... progress made on clinical, regulatory and operational fronts," ...
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, ... announced its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit ... Hotel, in Boston, MA. , The Omni Parker House Hotel, which is located at ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
Breaking Biology News(10 mins):